This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy
BMC Cancer Open Access 05 January 2021
-
Novel monoclonal antibodies against thymidine kinase 1 and their potential use for the immunotargeting of lung, breast and colon cancer cells
Cancer Cell International Open Access 16 April 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
26 October 2018
In the original version of Figure 1, the label on the y axis 'T cell-targeted' was incorrect and should be 'T cell-targeted immunomodulator'. The article has been corrected in the online version.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.O-T. is a paid board member of HemaCare. L. P. is a consultant to Cancer Research Institute and Canadian Cancer Trials Group.
Related links
RELATED LINKS
Supplementary information
Supplementary information
Supplementary Table (XLSX 23 kb)
Supplementary information
Trends of TAA-targeted IO agents in the past year. (PDF 183 kb)
Rights and permissions
About this article
Cite this article
Tang, J., Pearce, L., O'Donnell-Tormey, J. et al. Trends in the global immuno-oncology landscape. Nat Rev Drug Discov 17, 783–784 (2018). https://doi.org/10.1038/nrd.2018.167
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.167
This article is cited by
-
Massively parallel knock-in engineering of human T cells
Nature Biotechnology (2023)
-
Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma
Journal of Cancer Research and Clinical Oncology (2022)
-
Activation-induced cell death in CAR-T cell therapy
Human Cell (2022)
-
The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy
BMC Cancer (2021)
-
Industrializing engineered autologous T cells as medicines for solid tumours
Nature Reviews Drug Discovery (2021)